This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany. The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT. Study Objectives are to: 1. Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection 2. Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis 3. Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection 4. Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae 5. Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population 6. Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population 7. Estimate frequency of chlamydia testing in the overall study population
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID)
Timeframe: From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy
Timeframe: From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis tubal factor infertility
Timeframe: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis
Timeframe: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of proctitis
Timeframe: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of prostatitis
Timeframe: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of female/male infertility
Timeframe: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome
Timeframe: From Year 2008 to Year 2022
Time in days from first documented prevalent CT infection to first documented complication/sequelae diagnosis
Timeframe: From Year 2008 to Year 2022
Number of male and female participants with confirmed outpatient or any inpatient CT diagnosis at least 30 days after last CT diagnosis of any kind (reinfection)
Timeframe: From Year 2008 to Year 2022
Number of CT reinfections/episodes
Timeframe: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of other STI
Timeframe: From Year 2008 to Year 2022
Cost incurred from the number of physician contacts (of any specialty)
Timeframe: From Year 2008 to Year 2022
Costs incurred from the number of hospital admissions
Timeframe: From Year 2008 to Year 2022
Costs incurred for the number of prescriptions filled for any drug
Timeframe: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for any medical aid
Timeframe: From Year 2008 to Year 2022
Costs incurred for the number of physician contacts (of any specialty) related to CT or STI-diagnoses.
Timeframe: From Year 2008 to Year 2022
Costs incurred for the number of hospital admissions related to CT or STI-diagnoses.
Timeframe: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for CT-related antibiotics, dispensed within 30 days after CT diagnosis
Timeframe: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for medical aids related to CT or STI diagnoses
Timeframe: From Year 2008 to Year 2022
Total CT-/STI-unspecific health care costs (inpatient, outpatient, drugs, medical aids)
Timeframe: From Year 2008 to Year 2022
CT-/STI-unspecific outpatient costs
Timeframe: From Year 2008 to Year 2022
CT-/STI-unspecific inpatient costs
Timeframe: From Year 2008 to Year 2022
CT-/STI-unspecific drug cost
Timeframe: From Year 2008 to Year 2022
CT-/STI-unspecific medical aid costs
Timeframe: From Year 2008 to Year 2022
Outpatient costs that are related to cases with a confirmed CT diagnosis
Timeframe: From Year 2008 to Year 2022
Inpatient costs that are related to cases with any CT diagnosis
Timeframe: From Year 2008 to Year 2022
Outpatient costs that are related to cases with any confirmed STI diagnosis
Timeframe: From Year 2008 to Year 2022
Inpatient costs that are related to cases with any confirmed STI diagnosis
Timeframe: From Year 2008 to Year 2022
Costs of potentially CT-relevant antibiotics dispensed up to 30 days after confirmend outpatient or any inpatient CT diagnosis
Timeframe: From Year 2008 to Year 2022